Understanding ICH Q11—FDA's Guidance on the Development and Manufacture of Drug Substances - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Understanding ICH Q11—FDA's Guidance on the Development and Manufacture of Drug Substances
The author provides a review of FDA's guidance document, Guidance for Industry: Q11 Development and Manufacture of Drug Substances, and its relation to the International Conference on Harmonization's Q11 document and its application to the industry.

Pharmaceutical Technology
Volume 37, Issue 5, pp. 64-68

Finally, the identification of CQAs and understanding the influence certain material attributes exude on the manufacturing process should be considered a crucial aspect of the process. This is the area where implementing a control strategy and employing QRM becomes essential; and the concept of design space is introduced into the manufacturing equation. According to Q11, design space is the multidimensional combination and interaction of two elements: input variables and process parameters (1). Design space (as defined by the manufacturer) is subject to regulatory oversight by FDA. ICH Q8 (2.4) provides additional detail on the topic of design space.

The submission process for the enhanced approach: document requirements. There are mandatory submission requirements in support of manufacturing process development that must be considered by drug-substance manufacturers. The submission must contain sufficient detail to support the claim for product safety and efficacy needed for eventual commercialization. For example, the expectation is that the following documentation be included as part of the drug-substance submission.

  • An overall summary of the development process including: CQAs; description of design stages; description of material attributes; description of process parameters; and description and development of design spaces should be provided.
  • CQAs of the drug substance shall be listed.
  • A detailed discussion of the manufacturing process history needs to be provided.
  • Manufacturing development studies, including risk assessments employed in support of commercial development, including the control strategy, must be provided.

Description of process and process controls employed in manufacturing. It is imperative that the manufacturers of drug substances provide a detailed description of the manufacturing process and the processing controls employed. The most efficient way to adequate delineate processes is through the creation of flow charts. Flow charts are an inherent requirement, regardless of submission type. In fact, Q11 requires that a flow chart be provided as part of the submission process.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here